Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Thyroid Carcinoma, Anaplastic × combretastatin × Clear all

Phase

Status

Withdrawn 1 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Thyroid Neoplasms 1 Thyroid Carcinoma, Anaplastic 1

Interventions

fosbretabulin 2 Sorafenib 2 Paclitaxel 2 tislelizumab 1 surufatinib 1 pegfilgrastim 1 lenvatinib 1 efatutazone 1 combretastatin 1 Radiotherapy 1 PLX8394 1 Magnetic Resonance Spectroscopy 1 Imatinib Mesylate 1 Fluorodeoxyglucose F18 1 Filgrastim 1 Doxorubicin 1 Cisplatin 1 Carboplatin 1 CUDC-907 1 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00507429 2014-06-09

FACT

Mateon Therapeutics

Phase 2/3 Terminated

80 enrolled 10 charts

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡